Medically reviewed on Nov 15, 2018
(en a SID a nib)
- Enasidenib Mesylate
- IDH2 inhibitor
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
IDHIFA: 50 mg, 100 mg
Brand Names: U.S.
- Antineoplastic Agent, IDH2 Inhibitor
Enasidenib is a small molecule inhibitor of the enzyme isocitrate dehydrogenase 2 (IDH2); it targets the mutant IDH2 variants R140Q, R172S, and R172K at ~40-fold lower concentrations than the wild-type enzyme. Mutant IDH2 inhibition results in decreased 2-hydroxyglutarate (2-HG) levels, reduced abnormal histone hypermethylation, and restored myeloid differentiation (Stein 2017). Additionally, enasidenib reduces blast counts and increases percentages of mature myeloid cells.
In vitro data suggests that metabolism of parent drug is hepatic through multiple CYP enzymes (eg, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4), and by multiple UGTs (UGT1A1, UGT1A3, UGT1A4, UGT1A9, UGT2B7, and UGT2B15). The metabolite AGI-16903 is further metabolized by CYP1A2, CYP2C19, CYP3A4, UGT1A1, UGT1A3, and UGT1A9.
Feces (89%; 34% as unchanged drug); urine (11%; <1% as unchanged drug)
Time to Peak
Parent drug: 98.5%; AGI-16903 (metabolite): 96.6%
Use: Labeled Indications
Acute myeloid leukemia (relapsed/refractory): Treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an approved test
There are no contraindications listed in the manufacturer's labeling.
Note: Confirm IDH2 mutation status in the blood or bone marrow prior to treatment initiation. Enasidenib is associated with a moderate emetic potential; administer antiemetics prior to treatment to prevent nausea and vomiting.
Acute myeloid leukemia (relapsed/refractory): Oral: 100 mg once daily until disease progression or unacceptable toxicity; treat for a minimum of 6 months in patients without disease progression or unacceptable toxicity to allow time for clinical response.
Missed dose: If a dose is vomited, missed, or delayed, administer the dose as soon as possible on the same day; return to the normal administration schedule the following day.
Refer to adult dosing.
Dosing: Renal Impairment
CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, this level of renal function does not have a clinically significant effect on enasidenib pharmacokinetics.
CrCl <30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Hepatic Impairment
Hepatic impairment prior to treatment initiation:
Mild (total bilirubin within ULN and AST > ULN or total bilirubin 1 to 1.5 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, mild hepatic impairment does not have a clinically significant effect on enasidenib pharmacokinetics.
Moderate (total bilirubin >1.5 to 3 times ULN and any AST) to severe (total bilirubin >3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling.
Hepatotoxicity during treatment: Bilirubin >3 times ULN for ≥2 weeks without elevated transaminases or other hepatic disorders: Reduce dose to 50 mg once daily. Resume enasidenib at 100 mg once daily if bilirubin elevation resolves to <2 times ULN.
Dosing: Adjustment for Toxicity
Differentiation syndrome: If differentiation syndrome is suspected, initiate systemic corticosteroids (eg, dexamethasone IV or oral 10 mg twice daily) and monitor hemodynamics. Interrupt enasidenib for severe pulmonary symptoms requiring intubation or ventilator support and/or renal dysfunction persisting for more than 48 hours after systemic corticosteroid initiation. Resume enasidenib when signs/symptoms improve to ≤ grade 2. Taper systemic corticosteroids only after symptom resolution.
Noninfectious leukocytosis (WBC >30,000/mm3): Initiate hydroxyurea (per standard institutional practice); interrupt enasidenib if leukocytosis is not improved with hydroxyurea therapy, then resume enasidenib at 100 mg once daily when WBC <30,000/mm3.
Other toxicity: Grade 3 or higher (attributed to enasidenib [including tumor lysis syndrome]): Interrupt enasidenib until toxicity improves to ≤ grade 2. Resume enasidenib at 50 mg once daily; may increase to 100 mg once daily if toxicity resolves to ≤ grade 1. If ≥ grade 3 toxicity recurs, discontinue enasidenib.
Enasidenib is associated with a moderate emetic potential; administer antiemetics prior to treatment to prevent nausea and vomiting.
Oral: Administer orally once daily with or without food at approximately the same time each day. Swallow whole with a glass of water. Do not split or crush tablets.
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Keep bottle tightly closed. Protect from moisture; store in original bottle (with desiccant canister).
There are no known significant interactions.
Endocrine & metabolic: Decreased serum calcium (74%), decreased serum potassium (41%)
Gastrointestinal: Nausea (50%), diarrhea (43%), decreased appetite (34%), vomiting (34%), dysgeusia (12%)
Hematologic & oncologic: Abnormal phosphorus levels (27%; ≥3 grade: 8%; decreased), differentiation syndrome (14%), leukocytosis (12%; ≥3 grade: 6%; noninfectious)
Hepatic: Increased serum bilirubin (81%)
1% to 10%:
Hematologic & oncologic: Tumor lysis syndrome (6%)
Respiratory: Acute respiratory distress (≤10%), pulmonary edema (≤10%)
Concerns related to adverse effects:
• Differentiation syndrome: [US Boxed Warning]: Patients treated with enasidenib have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. Differentiation syndrome, which is associated with rapid proliferation and differentiation of myeloid cells, has occurred (with and without concomitant hyperleukocytosis) as early as 10 days and up to 5 months after initiating enasidenib. If differentiation syndrome is suspected, initiate IV or oral corticosteroids (eg, dexamethasone 10 mg twice daily); taper corticosteroids only after symptom resolution (symptoms may recur if steroid therapy is stopped early). Interrupt enasidenib therapy for severe pulmonary symptoms requiring intubation or ventilator support and/or renal dysfunction that continues for more than 48 hours after corticosteroid initiation; may resume therapy when signs/symptoms have improved. Hospitalization is recommended for patients with pulmonary and/or renal toxicity for close monitoring.
• Electrolyte imbalance: Hypocalcemia, hypokalemia, and hypophosphatemia have been reported.
• Hematologic effects: Noninfectious leukocytosis may occur due to myeloid proliferation leading to a rapid rise in white blood cell count. May require treatment with hydroxyurea (per institutional practice) and therapy interruption.
• Hepatotoxicity: Hyperbilirubinemia has been commonly reported; the majority of patients did not have concomitant transaminase elevation or other severe toxicity due to other liver disorders. Enasidenib may interfere with bilirubin metabolism through UGT1A1 inhibition. Persistent hyperbilirubinemia may require dosage reduction.
• GI toxicity: Enasidenib is associated with a moderate emetic potential; administer antiemetics prior to treatment to prevent nausea and vomiting. Nausea, vomiting, diarrhea, decreased appetite, and taste disturbances have been reported.
• Tumor lysis syndrome: Tumor lysis syndrome may occur; monitor electrolytes and renal function.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Appropriate use: Confirm IDH2 mutation status prior to therapy initiation. Information on tests approved to detect IDH2 mutation in AML may be found at http://www.FDA.gov/CompanionDiagnostics.
IDH2 mutation status (prior to treatment initiation); blood counts and blood chemistries prior to therapy initiation and every 2 weeks for at least the first 3 months; liver function tests; renal function; pregnancy test (prior to treatment in in females of reproductive potential); monitor for signs/symptoms of differentiation syndrome (eg, fever, cough, dyspnea, bone pain, rapid weight gain, edema, lymphadenopathy) and tumor lysis syndrome. Monitor adherence.
Based on the mechanism of action and data from animal reproduction studies, the use of enasidenib in pregnancy may cause fetal harm. Women of reproductive potential should have a pregnancy test prior to treatment initiation; effective contraception should be used during therapy and for at least 1 month after the last dose. Male patients with female partners of reproductive potential should also use effective contraception during therapy and for at least 1 month after the last dose. Based on animal data, treatment with enasidenib may impair fertility in females and males.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience nausea, vomiting, diarrhea, lack of appetite, or change in taste. Have patient report immediately to prescriber bone pain, cough, signs of a severe pulmonary disorder (lung or breathing problems like difficulty breathing, shortness of breath, or a cough that is new or worse), excessive weight gain, swelling of arms or legs, swollen glands, signs of kidney problems (urinary retention, hematuria, change in amount of urine passed, or weight gain), signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice), signs of electrolyte problems (mood changes, confusion, muscle pain or weakness, abnormal heartbeat, seizures, lack of appetite, or severe nausea or vomiting), jaundice, signs of infection, or signs of tumor lysis syndrome (tachycardia or abnormal heartbeat; any passing out; urinary retention; muscle weakness or cramps; nausea, vomiting, diarrhea or lack of appetite; or feeling sluggish) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about enasidenib
- Enasidenib Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: miscellaneous antineoplastics
- FDA Alerts (1)
Other brands: Idhifa